Wakabayashi (2023)

Diabetes

Endocrinology • Other Data • Japan

Study Metrics
Total Sample 96
Treatment Group 48
Control Group 48
Covariates 4
PICO Comparisons 3
Quality Indicators
Transparency High
DAG Usage No
QBA Performed No

Study Information

First Author: Wakabayashi
Publication Year: 2023
DOI: https://doi.org/10.1007/s40801-023-00353-7
Preprint: No preprint

Institution & Funding

Institutions: linical Study Support, Inc., Nagoya, Japan, Real-World Evidence and Data Assessment (READS), Graduate School of Medicine, Juntendo University, Department of Radiology, School of Medicine, Juntendo University
Funding: Declared: Research institute, private
Funding Institutions: This study was conducted as part of a joint research course (Real-World Evidence and Data Assessment) between Juntendo University and Shin Nippon Biomedical Laboratories, Ltd.

Study Context

Disease: Diabetes
Disease Category: Endocrinology
Data Type: Other
Number of Data Sources: 1
Geography: Japan
Eligible Sample: 96.0

Analytical Methods

Matching Method: 1:1 PS nearest-neighbor matching
Analysis Method: t-distribution
Estimand: ITT

Quality Methods

Directed Acyclic Graph (DAG) Not Used
Quantitative Bias Analysis (QBA) Not Performed

Target Trial Information

Target Trial Name: PRIME-V
Registration Number: UMIN000015170
Target Trial DOI: https://doi.org/10.1111/dom.13750

TTE vs RCT Comparisons

Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.

Change in HbA1c, %
COMPASS
MD Efficacy
Population

Japanese adults with T2D inadequately controlled with metformin and/or sulfonylurea

Intervention

Sitagliptin

Comparison

Pioglitazone

Outcome

Change in HbA1c, %

RCT Result

-0.28

95% CI: [-0.14, -0.16]


vs
TTE Result

-0.01

95% CI: [-0.25, 0.23]

Concordance Assessment
Confidence Interval Overlap: Yes
CIs overlap, suggesting concordance
Direction Agreement: Same Direction
Both point to similar conclusion
Change in HbA1c, %
Onishi 2013 et al.
MD Efficacy
Population

Insulin-naïve Japanese adults with T2D

Intervention

Insulin degludec/insulin aspart

Comparison

Insulin glargine

Outcome

Change in HbA1c, %

RCT Result

-0.28

95% CI: [-0.46, -0.10]


vs
TTE Result

0.46

95% CI: [-0.01, 0.94]

Concordance Assessment
Confidence Interval Overlap: No
CIs do not overlap
Direction Agreement: Different Direction
Different conclusions
Percentage changes in HbA1c levels (%)
PRIME-V
MD Efficacy
Population

Japanese adults with T2D treated with sitagliptin

Intervention

Ipragliflozin

Comparison

Metformin

Outcome

Percentage changes in HbA1c levels (%)

RCT Result

4.03

95% CI: [0.79, 7.27]


vs
TTE Result

-6.21

95% CI: [-11.01, -1.40]

Concordance Assessment
Confidence Interval Overlap: No
CIs do not overlap
Direction Agreement: Different Direction
Different conclusions

Transparency Indicators

Protocol Registration Available
Data Sharing Not Available
Code Sharing Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.

Conflicts & Funding

Conflicts of Interest: Declared: Financial
COI Institutions: Clinical Study Support Inc.
Funding Source: Declared: Research institute, private
Funding Institutions: This study was conducted as part of a joint research course (Real-World Evidence and Data Assessment) between Juntendo University and Shin Nippon Biomedical Laboratories, Ltd.